← Russell 3000 cross-section

CRL CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Trailing twelve months to 2026-06-27 · as filed 2026-08-05, not restated
Healthcare

Scale

Market cap
$14.4bn
Revenue TTM
$4.0bn
Net income TTM
$-238m
Free cash flow
$371m
Composite score
38.4
Sector rank
#551

Valuation

P / E
EV / EBITDA
36.6
EV / sales
3.6
FCF yield
2.57%
Earnings yield vs 10-yr
-6.39pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-6.0%
EBITDA margin
9.7%
ROE
-8.4%
ROIC
3.4%
Revenue growth
-0.7%

Insider activity, last 90 days

Net open-market
$-42.61m
Buyers
0
Sellers
6

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

For consolidated entities in which the Company owns or is exposed to less than 100% of the economics, the Company records net income attributable to noncontrolling interests in its unaudited condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained 9 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Pro forma financial information as well as the disclosure of actual revenue and operating income (loss) have not been presented separately because the Cambodian NHP Supplier’s financial results are not significant when compared to the Company’s consolidated financial results. …CHARLES RIVER LABORATORIES INTERNATIONAL, INC., 10-Q, period ended 2026-06-27, filed 2026-08-05

Read the full passage →